Introduction
============

Breast cancer has a substantial impact on the overall tumor burden in Pakistan comprising 40% of all female malignancies. In Pakistan, monoallelic germline mutations in the high- and moderate-penetrance breast cancer susceptibility genes *BRCA1*, *BRCA2*, *TP53*, *CHEK2*, and *RAD51C* account for approximately 25% of early-onset and familial breast cancer suggesting that other susceptibility gene(s) may be involved. Recently identified *PALB2* gene, a partner and localizer of BRCA2, acts as a link between *BRCA2* and *BRCA1* and enables DNA repair \[[@b1-crt-2018-356]\]. Biallelic mutations in *PALB2* (*FANCN*) cause Fanconi anemia, with clinical features similar to those caused by biallelic mutations in *BRCA2* (*FANCD1*) \[[@b2-crt-2018-356]\]. Monoallelic mutations in *PALB2* confer susceptibility to breast cancer suggesting that *PALB2* is another candidate to be a breast cancer susceptibility gene \[[@b3-crt-2018-356]\]. Deleterious *PALB2* mutations are estimated to confer a 35% lifetime risk of breast cancer for the carriers \[[@b4-crt-2018-356]\].

*PALB2* mutation screening in *BRCA1/2*-negative early-onset or familial breast cancer patients performed previously in different populations have yielded variable results. In a British study, monoallelic mutations in *PALB2* were identified in 1.1% of familial breast cancer patients (10/923) and were absent in controls (0/1,084) \[[@b3-crt-2018-356]\]. In a study conducted in Finland, a recurrent *PALB2* mutation, c.1592delT, was identified in 2.7% of familial breast cancer patients (3/113) and in 0.2% of controls (6/2,501) \[[@b5-crt-2018-356]\]. Mutations were identified in families from Europe, North America, and Australia at frequencies ranging from 0.3% to 5.5% \[[@b6-crt-2018-356]-[@b9-crt-2018-356]\], while mutations were absent in families from Canada \[[@b10-crt-2018-356]\], United States \[[@b11-crt-2018-356]\], and Chile \[[@b12-crt-2018-356]\].

In Asia, little is known about the contribution of *PALB2* mutations to early-onset and familial breast/ovarian cancer. Deleterious *PALB2* mutations were reported in families from China, Korea, and Malaysia/Singapore with frequencies varying from 0.8% to 1.6% \[[@b13-crt-2018-356]-[@b15-crt-2018-356]\] and were absent in Japanese families \[[@b16-crt-2018-356]\]. Given the limited data on genetic variability of *PALB2* in South Asia and the fact that only 25% of hereditary breast/ovarian cancer in Pakistan is attributed to germline mutations in *BRCA1/2*, *TP53*, *CHEK2*, and *RAD51C* \[[@b17-crt-2018-356]-[@b20-crt-2018-356]\], we assessed and report the prevalence of *PALB2* mutations in 370 early-onset and familial breast/ovarian cancer patients from this population, who had tested negative for mutations in these five breast cancer susceptibility genes. Functional and potentially functional mutations were screened in 372 healthy controls.

Materials and Methods
=====================

1. Study population
-------------------

The study included 370 early-onset and familial breast/ovarian cancer patients who were diagnosed with invasive breast cancer or epithelial ovarian cancer. The patients were evaluated and accrued to the study at the Shaukat Khanum Memorial Cancer Hospital and Research Center (SKMCH&RC) in Lahore, Pakistan, from June 2001 to January 2012. Patients were classified into six groups based on the age at the time of disease onset or family history of breast/ovarian cancer: A1, families with one female breast cancer diagnosed ≤ 30 years of age; A2, families with two first- or second-degree (through a male) female relatives diagnosed with breast cancer, at least one diagnosed ≤ 50 years of age; A3, families with at least three cases of breast cancer, at least one diagnosed ≤ 50 years of age; A4, families with one male breast cancer case diagnosed at any age; B, families with at least one female breast cancer and one ovarian cancer at any age, and C1, families with at least one ovarian cancer diagnosed ≤ 45 years of age. All index patients were previously tested and shown to be negative for deleterious mutations in the *BRCA1/2*, *CHEK2*, and *RAD51C* genes \[[@b17-crt-2018-356],[@b19-crt-2018-356],[@b20-crt-2018-356]\]. Of these index patients, 290 cases were also tested negative for disease-causative mutations in the *TP53* gene \[[@b18-crt-2018-356]\]. Patients with bilateral breast cancer or breast and ovarian cancer were considered as two independent primary cancers. A description of the study participants is shown in [Table 1](#t1-crt-2018-356){ref-type="table"}.

Immunohistochemical analyses of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression were performed on the breast tumor of the index patients as described previously \[[@b21-crt-2018-356]\].

The control group comprised of 372 healthy Pakistani women. Their recruitment details have been previously reported \[[@b22-crt-2018-356]\].

2. Molecular analyses
---------------------

Genomic DNA extraction was performed as described previously \[[@b22-crt-2018-356]\]. The complete coding sequence and exon-intron junctions of the *PALB2* gene (GenBank accession number NM_024675.3) were screened in the 370 index patients by denaturing high-performance liquid chromatography (DHPLC) analysis using WAVE 4500 DNA Fragment Analysis System (Transgenomics, Omaha, NE). Custom designed polymerase chain reaction (PCR)-primer pairs were used (Transgenomic Personalized Customer Support). DHPLC is a temperature modulated heteroduplex analysis which relies upon the physical changes in DNA molecules induced by mismatch heteroduplex formation \[[@b23-crt-2018-356]\]. Heteroduplexes were formed by denaturing the PCR product. The amplified product was loaded on a unique DNA separation matrix (Transgenomics) with homoduplexes and heteroduplexes eluting to it differentially under denaturing conditions. The elution profiles of heterduplexes were easily distinguished from those of homoduplexes. This technique has also been reported previously to detect *PALB2* mutations \[[@b11-crt-2018-356],[@b13-crt-2018-356],[@b24-crt-2018-356],[@b25-crt-2018-356]\]. When available, a mutation positive control for each exon was included in each analysis. Primer sequences, the setup of PCR reactions, cycling conditions, and DHPLC running conditions are available upon request.

Samples revealing variant DHPLC profiles were bi-directionally sequenced using an automated 3500 Genetic Analyzer (Applied Biosystems, Foster City, CA). The presence of identified pathogenic and *in silico*-predicted potentially deleterious *PALB2* mutations was assessed in 372 controls.

3. *In silico* analyses
-----------------------

All identified novel *PALB2* missense variants were analyzed for their potential effect on protein function by using five different computational algorithms, Align-GVGD, SIFT, MutationTaster, Polyphen-2, and SNAP2 in the default settings. In brief, Align-GVGD is based on the biophysical features of amino acids and multiple sequence alignments of protein (<http://agvgd.iarc.fr/agvgdinput.php>). SIFT predicts the evolutionary conservation of amino acids within protein families (<http://sift.jcvi.org>). MutationTaster prediction is based on regulatory features such as histone modification sites or transcription factor binding sites, evolutionary conservation of amino acid or nucleotide, and splice site predictions (<http://www.mutationtaster.org/>). PolyPhen-2 predicts the influence of an amino acid substitution on the structure and function of human protein (<http://genetics.bwh.harvard.edu/pph2/>). SNAP2 is based on multiple sequence alignment and predict changes on the secondary structure and compare the solvent accessibility for mutant and wild type proteins (<http://www.rostlab.org/services/snap/submit>) \[[@b26-crt-2018-356]\].

Novel intronic variants were also analyzed for their potential effect on splicing using the splice prediction algorithms, SpliceSiteFinder-like (<http://www.umd.be/searchSpliceSite.html>), MaxEntScan (<http://genes.mit.edu/burgelab/maxent/>), NNSPLICE (<http://www.fruitfly.org/seq_tools/splice.html>), GeneSplicer (<http://ccb.jhu.edu/software/genesplicer/>), and HumanSplice Finder (<http://www.umd.be/HSF/>) by means of the Alamut software interface (Interactive Biosoftware) in default settings. All these algorithms compare the splice site signal of wild type sequence with that of the mutated sequence. Moreover, one novel variant identified in 5′ untranslated region (5′ UTR) of *PALB2* was analyzed to predict its potential effect on transcription factor binding sites using PROMO (v3.0.2) on-line program (<http://alggen.lsi.upc.es/cgibin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3>).

4. Ethical statement
--------------------

Informed written consent was obtained from all study participants prior to providing a blood sample. The study was approved by the Institutional Review Board (IRB) of the SKMCH&RC (IRB approval number ONC-BRCA-001/2).

Results
=======

The present study included 370 early-onset and familial breast/ovarian cancer patients from Pakistan, who were negative for *BRCA1/2*, *TP53*, *CHEK2*, and *RAD51C* mutations. Of these, 180 were diagnosed with early-onset breast cancer (≤ 30 years of age), 127 belonged to families with two or more breast cancers, 23 to families with both breast and ovarian cancer, 22 to families with at least one ovarian cancer (diagnosed ≤ 45 years of age), and 18 to families with male breast cancer ([Table 1](#t1-crt-2018-356){ref-type="table"}). The median age of the disease onset was 30 years (range, 19 to 73 years) for female breast cancer (n=324), 47.5 years (range, 30 to 73 years) for male breast cancer (n=18), and 33 years (range, 22 to 60 years) for ovarian cancer (n=35). One-hundred and one index patients presented with triple-negative breast cancer (TNBC) and 217 with non-TNBC. The median age of the disease onset was 28 years (range, 19 to 67 years) for patients with TNBC and 30 years (range, 19 to 73 years) for those with non-TNBC.

Overall, 31 different heterozygous *PALB2* variants were detected. Of these, 13 were novel: one nonsense mutation, four missense variants, one silent variant, six intronic variants, and one 5′ UTR variant ([Table 2](#t2-crt-2018-356){ref-type="table"}). The remaining 18 variants have been previously reported in other populations: eight missense variants, four silent variants, five intronic variants, and one 5′ UTR variant.

The novel nonsense mutation at nucleotide position 2229 in exon 5, c.2229T\>A (p.Y743\*), was detected in a 29-year-old breast cancer patient of Punjabi ethnicity. The patient presented with a grade 3, invasive ductal carcinoma (IDC) of TNBC phenotype. A sister of the index patient was diagnosed with breast cancer at the age of 41 years.

The remaining 12 novel variants were analyzed for their potential functional effect by *in silico* analysis. Two missense variants p.G644R and p.E744K and the previously reported missense variant p.D498Y \[[@b14-crt-2018-356],[@b16-crt-2018-356],[@b27-crt-2018-356]\] were predicted to be potentially deleterious by three out of five *in silico* analysis tools ([Table 3](#t3-crt-2018-356){ref-type="table"}). The 5′ UTR variant c.-134\_-133-del-TCinsGGGT was predicted to create a splice donor site by three out of five splice-site prediction tools implying that it was disease associated ([Table 4](#t4-crt-2018-356){ref-type="table"}). This variant was also predicted to create the binding sites for two transcription factors, GR-alpha (T00337) and RXR-alpha (T01345), using PROMO (v3.0.2) on-line program.

The potentially disease-causative missense mutations p.G644R and p.E744K were identified in two women of Punjabi or Pathan ethnic group, who were diagnosed with early-onset breast cancer at the ages of 30 years, respectively. Their tumors were grade 3 IDCs, which were, ER-positive, PR-positive, and HER2-negative. The other missense mutation, p.D498Y, was identified in a patient of Pathan origin, who was diagnosed with synchronous bilateral breast cancer at 39 years of age. Left-sided breast tumor was grade 2 IDC and ER-positive, PR-negative, and HER2-negative. Right-sided breast tumor was grade 3 IDC and ER-negative, PR-negative, and HER2-positive. The index patient reported a family history of breast cancer and other cancers. The mother and one sister of the index patient were diagnosed with breast cancer at the ages of 53 and 44 years, respectively. Her father was diagnosed with lung cancer at age 69. One sister and paternal uncle of the index patient were diagnosed to have brain cancer at the ages of 34 and 48 years, respectively.

The 5′ UTR variant, c.-134\_-133delTCinsGGGT, was identified in an early-onset breast cancer patient of Pathan ethnic group, who was diagnosed with disease at 26 years of age. Her tumor was a grade 2 IDC of TNBC phenotype. This patient had also been diagnosed with adenocarcinoma of the rectum at 25 years of age.

The nonsense mutation and the four *in silico*-predicted potentially functional mutations were not identified in 372 controls implying that they were disease-causative ([Table 2](#t2-crt-2018-356){ref-type="table"}). The remaining 17 variants (seven missense variants, four silent variants, five intronic variants, and one 5' UTR variant) were reported previously and classified as polymorphisms ([Table 2](#t2-crt-2018-356){ref-type="table"}).

Discussion
==========

In this large study conducted in Pakistan, we assessed for the first time the prevalence of *PALB2* germline mutations in 370 early-onset and familial breast/ovarian cancer patients negative for *BRCA1/2*, *TP53*, *CHEK2*, and *RAD51C* mutations. One novel deleterious and four *in silico*-predicted potentially functional *PALB2* mutations (including three novels) were identified. Our study provides additional data on the contribution of *PALB2* mutations to hereditary breast/ovarian cancer in an Asian population from Pakistan.

The novel pathogenic *PALB2* mutation (p.Y743\*) was identified in 0.8% of families with two or more breast cancers (1/127). Similar mutation frequencies were reported in other Asian breast and/or ovarian cancer families from Saudi Arabia (5/725, 0.7%) \[[@b28-crt-2018-356]\], China (3/360, 0.8%) \[[@b13-crt-2018-356]\], and Korea (2/235, 0.8%) \[[@b14-crt-2018-356]\]. Higher frequencies were reported in studies conducted in India (9/752, 1.2%) \[[@b29-crt-2018-356]\], Malaysia/Singapore (2/122, 1.6%) \[[@b15-crt-2018-356]\], China (2/108, 1.8%) \[[@b30-crt-2018-356]\], and Korea (3/120, 2.5%) \[[@b31-crt-2018-356]\]. This could be due to the Next-Generation Sequencing approach employed in most of these studies. Furthermore, our results are likely to underestimate the *PALB2* mutation frequencies as the recently reported large genomic rearrangements were not screened \[[@b29-crt-2018-356],[@b32-crt-2018-356]\]. Mutations were not identified in few studies from Japan \[[@b16-crt-2018-356]\], Chile \[[@b12-crt-2018-356]\], and United States \[[@b11-crt-2018-356]\]. In European and North American studies including more than 100 families from Czech Republic, France, Ireland, Germany, Poland, Italy, Finland, Canada, United States, and Australia the mutation frequencies ranged from 0.3% to 5.5% \[[@b5-crt-2018-356]-[@b9-crt-2018-356],[@b33-crt-2018-356]-[@b38-crt-2018-356]\]. Altogether these findings suggest that *PALB2* mutations account for a small proportion of hereditary breast/ovarian cancer in most populations including the Pakistani population.

Four *in silico*-predicted potentially functional *PALB2* mutations (p.G644R, p.E744K, p.D498Y, and c.-134\_-133del-TCinsGGGT) were also identified in this study. The novel missense mutations p.G644R and p.E744K, each identified in an early-onset breast cancer patient, were located in the highly conserved MRG15-binding domain of PALB2 spanning amino acid residues 611 to 764. They may ablate PALB2 interacting with MRG15, which may result in impaired DNA repair \[[@b39-crt-2018-356]\] leading to genomic instability and cancer. The p.G644R variant was predicted to be deleterious by SIFT, Align-GVGD and SNAP-2 algorithms, while it was predicted as benign by PolyPhen-2 and MutationTaster. The differential prediction may be due to the underlying algorithm's differences as SIFT uses evolutionary sequence conservation whereas PolyPhen-2 utilizes protein structure information \[[@b40-crt-2018-356]\]. Since none of these algorithms is 100% predictive, a consensus prediction is reported to improve the prediction performance \[[@b41-crt-2018-356]\]. Overall, this variant was considered as deleterious by three of the five protein function algorithms. The missense mutation p.D498Y was identified in a familial breast cancer patient. Due to lack of DNA samples, co-segregation of the mutation with breast cancer could not be studied. Previously, this was also reported as an *in silico*-predicted potentially disease-causative mutation in families from Korea, Japan, and Australia \[[@b14-crt-2018-356],[@b16-crt-2018-356],[@b27-crt-2018-356]\]. The 5′ UTR variant, c.-134\_-133delTCinsGGGT, was detected in a patient with personal history of breast and rectal cancer. It was predicted to result in activation of a cryptic splice site. This variant was also predicted to affect two transcription factor binding sites and may alter the promoter activity of *PALB2*. None of these mutations were detected in 372 controls further suggesting that they are disease-causative; however, functional analyses of the potentially disease-causative mutations will be required for final mutation classification.

No deleterious *PALB2* mutations were identified in early-onset breast cancer patients, families with breast and ovarian cancer, ovarian cancer, or male breast cancer. These findings are in keeping with those previously reported in families from Turkey \[[@b42-crt-2018-356]\], Finland \[[@b43-crt-2018-356]\], Japan \[[@b16-crt-2018-356]\], the Netherlands \[[@b44-crt-2018-356]\], Spain \[[@b32-crt-2018-356]\], Italy \[[@b45-crt-2018-356]\], and Australia \[[@b46-crt-2018-356]\]. In contrast, *PALB2* mutations have also been reported in families from Poland \[[@b37-crt-2018-356]\], Italy \[[@b47-crt-2018-356]\], Czech Republic \[[@b8-crt-2018-356]\], and China \[[@b13-crt-2018-356]\]. These findings suggest that *PALB2* mutations may not substantially confer susceptibility to early-onset breast cancer patients and patients from breast and ovarian cancer, male breast cancer or ovarian cancer families.

In our study, the breast tumors associated with the *PALB2* truncating (p.Y743\*) and *in silico*-predicted potentially functional (p.D498Y, p.G644R, and p.E744K) mutations presented with high-grade tumors of IDC histology, which is consistent with previous studies conducted among Asian \[[@b13-crt-2018-356]-[@b15-crt-2018-356]\], European \[[@b24-crt-2018-356],[@b25-crt-2018-356],[@b48-crt-2018-356]\], and North-American patients \[[@b49-crt-2018-356]\]. In the Pakistani study, the breast tumor linked with the truncating mutation displayed the TNBC phenotype, in agreement with other studies from Europe, North-America and Australia \[[@b50-crt-2018-356]-[@b52-crt-2018-356]\]. Breast tumors associated with missense mutations were ER-positive, PR-positive, and HER2-negative. Similar hormone receptor expression patterns were also reported in breast tumors of Asian \[[@b14-crt-2018-356]\], European \[[@b48-crt-2018-356]\], and North-American patients \[[@b53-crt-2018-356]\], who harbored *PALB2* truncating mutations. The differential expression of hormone receptors could be due to mutation-specific tumor phenotypes in the studied population.

In summary, we have identified one novel pathogenic and four potentially pathogenic *PALB2* mutations, three being novel in 370 Pakistani early-onset and familial breast/ovarian cancer patients, negative for mutations in *BRCA1/2*, *TP53*, *CHEK2*, and *RAD51C*. The frequency of *PALB2* mutations in patients with familial breast cancer was 0.8% (1/127), while no mutations were identified in early-onset breast cancer patients and patients from breast and ovarian cancer, male breast cancer or ovarian cancer families. Our findings suggest a marginal contribution of *PALB2* mutations to breast cancer susceptibility in Pakistan.
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###### 

Frequency of *PALB2* mutations according to family structure and TNBC subtype

  Risk group   Phenotype of families                      Families^[a)](#tfn1-crt-2018-356){ref-type="table-fn"}^   *PALB2* mutation
  ------------ ------------------------------------------ --------------------------------------------------------- ------------------
  \-           All families                               370                                                       1 (0.3)
  \-           Female breast cancer families              307                                                       1 (0.3)
  A1           1 case ≤ 30 years                          180                                                       0
  A2+A3        ≥ 2 cases, ≥ 1 diagnosed ≤ 50 years        127                                                       1 (0.8)
  A4           Male breast cancer families                                                                          
  \-           ≥ 1 case of male breast cancer             18                                                        0
  B            Breast-ovarian cancer families                                                                       
  \-           ≥ 1 breast cancer and ≥ 1 ovarian cancer   23                                                        0
  \-           Ovarian cancer families                                                                              
  C1           ≥ 1 case(s), ≥ 1 diagnosed ≤ 45 years      22                                                        0
  Subtype      \-                                                                                                   
  TNBC         \-                                         101                                                       1 (1.0)
  Non-TNBC     \-                                         217                                                       0
  Unknown      \-                                         24                                                        0

Values are presented as number (%). TNBC, triple negative breast cancer.

All families were negative for *BRCA1/2, CHEK2,* and *RAD51C* germline mutations; 290 families were negative for *TP53* germline mutations.

###### 

*PALB2* germline mutations in early-onset and familial breast/ovarian cancer patients from Pakistan

  Location    Coding (c.) DNA sequence^[a)](#tfn2-crt-2018-356){ref-type="table-fn"}^ (amino acid change)   Effect      SNP Link^[b)](#tfn3-crt-2018-356){ref-type="table-fn"}^   Classification                                      Prevalence, n (%)   Previously described   
  ----------- --------------------------------------------------------------------------------------------- ----------- --------------------------------------------------------- --------------------------------------------------- ------------------- ---------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Exon 5      c.2229T\>A (p.Y743\*)^[c)](#tfn4-crt-2018-356){ref-type="table-fn"}^                          Nonsense    rs730881888                                               M                                                   1 (0.3)             0                      No
  Exon 4      c.1492G\>T (p.D498Y)                                                                          Missense    rs75023630                                                M?^[d)](#tfn5-crt-2018-356){ref-type="table-fn"}^   1 (0.3)             0                      Yes^[e)](#tfn6-crt-2018-356){ref-type="table-fn"}^
  Exon 5      c.1930G\>A (p.G644R)^[c)](#tfn4-crt-2018-356){ref-type="table-fn"}^                           Mis sense   \-                                                        M?^[d)](#tfn5-crt-2018-356){ref-type="table-fn"}^   1 (0.3)             0                      No
  Exon 5      c.2230G\>A (p.E744K)^[c)](#tfn4-crt-2018-356){ref-type="table-fn"}^                           Missense    rs62625278                                                M?^[d)](#tfn5-crt-2018-356){ref-type="table-fn"}^   1 (0.3)             0                      No
  5′ UTR      c.-134\_-133delTCinsGGGT^[c)](#tfn4-crt-2018-356){ref-type="table-fn"}^                       5′ UTR      \-                                                        M?^[d)](#tfn5-crt-2018-356){ref-type="table-fn"}^   1 (0.3)             0                      No
  Exon 4      c.768C\>T (p.S256S)                                                                           Silent      rs45487491                                                P                                                   1 (0.3)             \-                     Yes^[e)](#tfn6-crt-2018-356){ref-type="table-fn"},[f)](#tfn7-crt-2018-356){ref-type="table-fn"}^
  Exon 4      c.899C\>T (p.T300I)                                                                           Missense    \-                                                        P                                                   3 (0.8)             \-                     Yes^[e)](#tfn6-crt-2018-356){ref-type="table-fn"}^
  Exon 4      c.1010T\>C (p.L337S)                                                                          Missense    rs45494092                                                P                                                   4 (1.1)             \-                     Yes^[e)](#tfn6-crt-2018-356){ref-type="table-fn"},[f)](#tfn7-crt-2018-356){ref-type="table-fn"},[g)](#tfn8-crt-2018-356){ref-type="table-fn"},[h)](#tfn9-crt-2018-356){ref-type="table-fn"}^
  Exon 4      c.1311A\>G (p.K437K)^[c)](#tfn4-crt-2018-356){ref-type="table-fn"}^                           Silent      rs190489275                                               P                                                   1 (0.3)             \-                     No
  Exon 4      c.1572A\>G (p.S524S)                                                                          Silent      rs45472400                                                P                                                   1 (0.3)             \-                     Yes^[e)](#tfn6-crt-2018-356){ref-type="table-fn"},[f)](#tfn7-crt-2018-356){ref-type="table-fn"},[g)](#tfn8-crt-2018-356){ref-type="table-fn"},[h)](#tfn9-crt-2018-356){ref-type="table-fn"}^
  Exon 4      c.1676A\>G (p.Q559R)                                                                          Missense    rs152451                                                  P                                                   67 (18.0)           \-                     Yes^[e)](#tfn6-crt-2018-356){ref-type="table-fn"},[f)](#tfn7-crt-2018-356){ref-type="table-fn"},[g)](#tfn8-crt-2018-356){ref-type="table-fn"},[h)](#tfn9-crt-2018-356){ref-type="table-fn"}^
  Exon 5      c.2014G\>C (p.E672Q)                                                                          Missense    rs45532440                                                P                                                   27 (7.3)            \-                     Yes^[e)](#tfn6-crt-2018-356){ref-type="table-fn"},[f)](#tfn7-crt-2018-356){ref-type="table-fn"},[g)](#tfn8-crt-2018-356){ref-type="table-fn"},[h)](#tfn9-crt-2018-356){ref-type="table-fn"}^
  Exon 5      c.2135C\>T (p.A712V)                                                                          Missense    rs141458731                                               P                                                   1 (0.3)             \-                     Yes^[e)](#tfn6-crt-2018-356){ref-type="table-fn"}^
  Exon 5      c.2244A\>G (p.T748T)                                                                          Silent      rs750048627                                               P                                                   1 (0.3)             \-                     Yes^[e)](#tfn6-crt-2018-356){ref-type="table-fn"}^
  Exon 5      c.2329G\>A (p.D777N)^[c)](#tfn4-crt-2018-356){ref-type="table-fn"}^                           Missense    rs148026749                                               P^[c)](#tfn4-crt-2018-356){ref-type="table-fn"}^    1 (0.3)             \-                     No
  Exon 7      c.2590C\>T (p.P864S)                                                                          Missense    rs45568339                                                P                                                   1 (0.3)             \-                     Yes^[e)](#tfn6-crt-2018-356){ref-type="table-fn"},[f)](#tfn7-crt-2018-356){ref-type="table-fn"},[g)](#tfn8-crt-2018-356){ref-type="table-fn"},[h)](#tfn9-crt-2018-356){ref-type="table-fn"}^
  Exon 9      c.2993G\>A (p.G998E)                                                                          Missense    rs45551636                                                P                                                   19 (5.1)            \-                     Yes^[e)](#tfn6-crt-2018-356){ref-type="table-fn"},[f)](#tfn7-crt-2018-356){ref-type="table-fn"},[g)](#tfn8-crt-2018-356){ref-type="table-fn"},[h)](#tfn9-crt-2018-356){ref-type="table-fn"}^
  Exon 12     c.3239A\>G (p.K1080R)^[c)](#tfn4-crt-2018-356){ref-type="table-fn"}^                          Missense    \-                                                        P^[c)](#tfn4-crt-2018-356){ref-type="table-fn"}^    1 (0.3)             \-                     No
  Exon 12     c.3300T\>G (p.T1100T)                                                                         Silent      rs45516100                                                P                                                   22 (5.9)            \-                     Yes^[e)](#tfn6-crt-2018-356){ref-type="table-fn"},[f)](#tfn7-crt-2018-356){ref-type="table-fn"},[g)](#tfn8-crt-2018-356){ref-type="table-fn"},[h)](#tfn9-crt-2018-356){ref-type="table-fn"}^
  5′ UTR      c.-47G\>A                                                                                     5′ UTR      rs8053188                                                 P                                                   23 (6.2)            \-                     Yes^[g)](#tfn8-crt-2018-356){ref-type="table-fn"},[h)](#tfn9-crt-2018-356){ref-type="table-fn"}^
  Intron 3    c.211+46C\>A^[c)](#tfn4-crt-2018-356){ref-type="table-fn"}^                                   Intronic    \-                                                        P^[c)](#tfn4-crt-2018-356){ref-type="table-fn"}^    1 (0.3)             \-                     No
  Intron 3    c.212-58A\>C                                                                                  Intronic    rs80291632                                                P                                                   26 (7.0)            \-                     Yes^[g)](#tfn8-crt-2018-356){ref-type="table-fn"},[h)](#tfn9-crt-2018-356){ref-type="table-fn"}^
  Intron 3    c.212-21\_-15dupATACATT^[c)](#tfn4-crt-2018-356){ref-type="table-fn"}^                        Intronic    \-                                                        P^[c)](#tfn4-crt-2018-356){ref-type="table-fn"}^    1 (0.3)             \-                     No
  Intron 3    c.212-21A\>G^[c)](#tfn4-crt-2018-356){ref-type="table-fn"}^                                   Intronic    \-                                                        P^[c)](#tfn4-crt-2018-356){ref-type="table-fn"}^    1 (0.3)             \-                     No
  Intron 4    c.1684+39\_+41dupTGA                                                                          Intronic    \-                                                        P                                                   5 (1.3)             \-                     Yes^[h)](#tfn9-crt-2018-356){ref-type="table-fn"}^
  Intron 6    c.2586+58C\>T                                                                                 Intronic    rs249954                                                  P                                                   162 (43.7)          \-                     Yes^[g)](#tfn8-crt-2018-356){ref-type="table-fn"},[h)](#tfn9-crt-2018-356){ref-type="table-fn"}^
  Intron 6    c.2587-38C\>G                                                                                 Intronic    rs180177119                                               P                                                   4 (1.1)             \-                     Yes^[g)](#tfn8-crt-2018-356){ref-type="table-fn"},[h)](#tfn9-crt-2018-356){ref-type="table-fn"}^
  Intron 7    c.2749-115T\>A^[c)](#tfn4-crt-2018-356){ref-type="table-fn"}^                                 Intronic    rs147911546                                               P^[c)](#tfn4-crt-2018-356){ref-type="table-fn"}^    4 (1.1)             \-                     No
  Intron 10   c.3114-51T\>A                                                                                 Intronic    rs249936                                                  P                                                   6 (1.6)             \-                     Yes^[h)](#tfn9-crt-2018-356){ref-type="table-fn"}^
  Intron 11   c.3201+5\_+8delGTAA^[c)](#tfn4-crt-2018-356){ref-type="table-fn"}^                            Intronic    \-                                                        P^[c)](#tfn4-crt-2018-356){ref-type="table-fn"}^    1 (0.3)             \-                     No
  Intron 11   c.3201+30T\>C^[c)](#tfn4-crt-2018-356){ref-type="table-fn"}^                                  Intronic    \-                                                        P^[c)](#tfn4-crt-2018-356){ref-type="table-fn"}^    1 (0.3)             \-                     No

M, mutation; M?, potentially deleterious mutation based on three out of five in silico tools applied; P, polymorphism.

Nomenclature follows Human Genome Variation Society (HGVS) (<http://www.hgvs.org>). Numbering start at the first A of the first coding ATG (located in exon 1) of NCBI GenBank Accession NM_024675.3,

Link to NCBI SNP database (<http://ncbi.nlm.nih.gov/projects/SNP/>),

Novel germline alterations,

Classification of nucleotide alteration is based on in silico analyses,

Thompson et al. \[[@b27-crt-2018-356]\],

Rahman et al. \[[@b3-crt-2018-356]\],

Blanco et al. \[[@b32-crt-2018-356]\],

Damiola et al. \[[@b7-crt-2018-356]\].

###### 

*In silico* analyses of *PALB2* coding variants identified in early-onset and familial breast/ovarian cancer patients from Pakistan

  Coding variant                                                         *In silico* prediction tool   Consensus^[a)](#tfn10-crt-2018-356){ref-type="table-fn"}^                                  
  ---------------------------------------------------------------------- ----------------------------- ----------------------------------------------------------- ----- -------------- --------- -------------------
  c.1492G\>T (p.D498Y)^[b)](#tfn11-crt-2018-356){ref-type="table-fn"}^   Possibly damaging             Deleterious                                                 C0    Polymorphism   Effect    Deleterious (3/5)
  c.1930G\>A (p.G644R)                                                   Benign                        Deleterious                                                 C15   Polymorphism   Effect    Deleterious (3/5)
  c.2230G\>A (p.E744K)                                                   Possibly damaging             Deleterious                                                 C0    Polymorphism   Effect    Deleterious (3/5)
  c.2329G\>A (p.D777N)                                                   Benign                        Tolerated                                                   C0    Polymorphism   Neutral   Benign
  c.3239A\>G (p.K1080R)                                                  Probably damaging             Tolerated                                                   C0    Polymorphism   Neutral   Benign

PolyPhen-2, Polymorphism Phenotyping ver. 2; SIFT, Sorting Intolerant From Tolerant; Align GVGD, Alignment of Grantham Variable and Grantham Deviation; SNAP2, Screening for Non-Acceptable Polymorphisms 2.

The variant is considered as deleterious by three of the five protein function algorithms,

Previously reported missense variant \[[@b14-crt-2018-356],[@b16-crt-2018-356],[@b27-crt-2018-356]\].

###### 

*In silico* analyses of *PALB2* noncoding variants identified in early-onset and familial breast/ovarian cancer patients from Pakistan

  Noncoding variant          Splice-site predictions   Consensus^[a)](#tfn12-crt-2018-356){ref-type="table-fn"},[b)](#tfn13-crt-2018-356){ref-type="table-fn"}^                                                      
  -------------------------- ------------------------- ---------------------------------------------------------------------------------------------------------- ---------------- ----------------- --------------- -------------------
  c.-134\_-133delTCinsGGGT   NE                        D (0 to 6.2)                                                                                               NE               D (0 to 4.1)      D (0 to 82.1)   Deleterious (3/5)
  c.211+46C\>A               NE                        A (8.6 to 6.8)                                                                                             A (1.0 to 0.7)   NE                NE              Benign
  c.212-21\_-15dupATACATT    NE                        NE                                                                                                         NE               NE                NE              Benign
  c.212-21A\>G               NE                        NE                                                                                                         NE               NE                NE              Benign
  c.2749-115T\>A             NE                        A (4.7 to 2.7)                                                                                             NE               NE                NE              Benign
  c.3201+5\_+8delGTAA        NE                        D (11.0 to 5.5)                                                                                            NE               D (4.43 to 1.1)   NE              Benign
  c.3201+30T\>C              NE                        NE                                                                                                         NE               NE                NE              Benign

D, donor; NE, no effect; A, acceptor.

The variant is considered as deleterious by three of the five splice-site prediction algorithms,

\> 20% change in score (i.e., a wild-type splice-site score decreases, and/or a cryptic splice-site score increases) is considered as significant.
